ACB
Price
$2.84
Change
-$0.03 (-1.05%)
Updated
Jun 23, 04:01 PM (EDT)
Capitalization
179.26M
50 days until earnings call
Intraday BUY SELL Signals
CPHI
Price
$0.70
Change
-$0.03 (-4.11%)
Updated
Jun 23, 04:34 PM (EDT)
Capitalization
29.61M
Intraday BUY SELL Signals
Interact to see
Advertisement

ACB vs CPHI

ACB vs CPHI Comparison Chart in %
View a ticker or compare two or three
VS
ACB vs. CPHI commentary
Jun 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACB is a StrongBuy and CPHI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 23, 2026
Stock price -- (ACB: $2.87 vs. CPHI: $0.73)
Brand notoriety: ACB: Notable vs. CPHI: Not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACB: 113% vs. CPHI: 15%
Market capitalization -- ACB: $179.26M vs. CPHI: $29.61M
ACB [@Pharmaceuticals: Generic] is valued at $179.26M. CPHI’s [@Pharmaceuticals: Generic] market capitalization is $29.61M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACB’s FA Score shows that 0 FA rating(s) are green whileCPHI’s FA Score has 0 green FA rating(s).

  • ACB’s FA Score: 0 green, 5 red.
  • CPHI’s FA Score: 0 green, 5 red.
According to our system of comparison, CPHI is a better buy in the long-term than ACB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACB’s TA Score shows that 4 TA indicator(s) are bullish while CPHI’s TA Score has 3 bullish TA indicator(s).

  • ACB’s TA Score: 4 bullish, 6 bearish.
  • CPHI’s TA Score: 3 bullish, 2 bearish.
According to our system of comparison, CPHI is a better buy in the short-term than ACB.

Price Growth

ACB (@Pharmaceuticals: Generic) experienced а -2.71% price change this week, while CPHI (@Pharmaceuticals: Generic) price change was -4.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.70%. For the same industry, the average monthly price growth was +0.08%, and the average quarterly price growth was +8.31%.

Reported Earning Dates

ACB is expected to report earnings on Aug 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.70% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACB($179M) has a higher market cap than CPHI($29.6M). ACB YTD gains are higher at: -31.991 vs. CPHI (-39.620). CPHI has higher annual earnings (EBITDA): -1.21M vs. ACB (-48.09M). ACB has more cash in the bank: 108M vs. CPHI (168K). CPHI has less debt than ACB: CPHI (3.86M) vs ACB (101M). ACB has higher revenues than CPHI: ACB (373M) vs CPHI (3.99M).
ACBCPHIACB / CPHI
Capitalization179M29.6M605%
EBITDA-48.09M-1.21M3,959%
Gain YTD-31.991-39.62081%
P/E Ratio19.44N/A-
Revenue373M3.99M9,344%
Total Cash108M168K64,286%
Total Debt101M3.86M2,619%
FUNDAMENTALS RATINGS
ACB vs CPHI: Fundamental Ratings
ACB
CPHI
OUTLOOK RATING
1..100
629
VALUATION
overvalued / fair valued / undervalued
1..100
52
Fair valued
34
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9696
PRICE GROWTH RATING
1..100
8058
P/E GROWTH RATING
1..100
88100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CPHI's Valuation (34) in the Pharmaceuticals Generic industry is in the same range as ACB (52) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to ACB’s over the last 12 months.

CPHI's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as ACB (100) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to ACB’s over the last 12 months.

CPHI's SMR Rating (96) in the Pharmaceuticals Generic industry is in the same range as ACB (96) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to ACB’s over the last 12 months.

CPHI's Price Growth Rating (58) in the Pharmaceuticals Generic industry is in the same range as ACB (80) in the Pharmaceuticals Other industry. This means that CPHI’s stock grew similarly to ACB’s over the last 12 months.

ACB's P/E Growth Rating (88) in the Pharmaceuticals Other industry is in the same range as CPHI (100) in the Pharmaceuticals Generic industry. This means that ACB’s stock grew similarly to CPHI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACBCPHI
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bearish Trend 2 days ago
78%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 27 days ago
76%
Bullish Trend 8 days ago
80%
Declines
ODDS (%)
Bearish Trend 9 days ago
85%
Bearish Trend 2 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ACB
Daily Signal:
Gain/Loss:
CPHI
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BRNS0.700.04
+5.39%
Barinthus Biotherapeutics plc
FRAF62.010.56
+0.91%
Franklin Financial Services Corp
IMTX9.78N/A
N/A
Immatics NV
ENIC4.56-0.01
-0.22%
Enel Chile SA
HON228.11-0.90
-0.39%
Honeywell International

ACB and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACB has been closely correlated with CGC. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if ACB jumps, then CGC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACB
1D Price
Change %
ACB100%
-2.05%
CGC - ACB
70%
Closely correlated
-0.85%
OGI - ACB
67%
Closely correlated
+0.34%
CRON - ACB
66%
Loosely correlated
-2.21%
SNDL - ACB
65%
Loosely correlated
-1.06%
TRLV - ACB
60%
Loosely correlated
-9.70%
More